DRG Oncology experts joined nearly 40,000 oncology professionals at the 2018 Annual Meeting to get a download of the latest data and innovations in the space.

Out of the many sessions and abstracts we reviewed, we compiled a brief of key meeting highlights and industry implications for our oncology clients as they plan for the future:

  • Merck set to consolidate its dominant position in first-line metastatic NSCLC
  • ASCO 2018 highlights difficulties developing combinations with immune checkpoint inhibitors
  • Innovative therapies for bladder cancer outside of the immune space
  • Last, but not least: KEYNOTE-045 in bladder cancer
  • Post ASCO Update: Avastin’s FDA approval in first-line ovarian cancer – what are the market implications?


Biotech set for good start to 2021

View Now